Moderna eyes Omicron-specific jab in 2022

By Georgie Moore and Dominic Giannini
Updated January 27 2022 - 7:41pm, first published 7:35pm
Pharmaceutical company Moderna is testing its Omicron-specific COVID-19 booster vaccine.
Pharmaceutical company Moderna is testing its Omicron-specific COVID-19 booster vaccine.

Pharmaceutical company Moderna aims to have its Omicron-specific COVID-19 booster vaccine on the market by the third quarter of 2022.

Subscribe now for unlimited access.

$0/

(min cost $0)

or signup to continue reading

See subscription options

Get the latest Singleton news in your inbox

Sign up for our newsletter to stay up to date.

We care about the protection of your data. Read our Privacy Policy.